- Report
- July 2025
- 120 Pages
Global
From €5243EUR$5,950USD£4,605GBP
- Report
- August 2025
- 199 Pages
Global
From €3124EUR$3,545USD£2,744GBP
€3471EUR$3,939USD£3,049GBP
- Report
- March 2025
- 200 Pages
Global
From €3957EUR$4,490USD£3,475GBP
- Report
- November 2025
- 187 Pages
Global
From €3124EUR$3,545USD£2,744GBP
€3471EUR$3,939USD£3,049GBP
- Report
- December 2025
- 375 Pages
Global
From €5155EUR$5,850USD£4,528GBP
- Report
- December 2025
- 224 Pages
Global
From €5155EUR$5,850USD£4,528GBP
- Report
- February 2025
- 200 Pages
Global
From €3957EUR$4,490USD£3,475GBP
- Report
- November 2022
- 141 Pages
Global
From €4362EUR$4,950USD£3,831GBP
- Report
- March 2023
- 150 Pages
Global
From €5243EUR$5,950USD£4,605GBP
- Report
- November 2022
- 111 Pages
Global
From €3965EUR$4,500USD£3,483GBP
- Report
- April 2023
- 120 Pages
Global
From €4186EUR$4,750USD£3,677GBP
- Report
- October 2023
- 183 Pages
Global
From €3965EUR$4,500USD£3,483GBP
- Report
- May 2024
- 200 Pages
Global
From €3657EUR$4,150USD£3,212GBP
- Report
- April 2023
- 115 Pages
Global
From €4186EUR$4,750USD£3,677GBP
- Report
- April 2023
- 117 Pages
Global
From €4186EUR$4,750USD£3,677GBP
Hodgkin Lymphoma (HL) is a type of cancer that affects the lymphatic system, a part of the immune system. It is characterized by the presence of a type of cell called the Reed-Sternberg cell. HL is the most common type of lymphoma in the United States, and is most common in young adults. Treatment for HL typically involves chemotherapy, radiation therapy, and/or stem cell transplantation.
The oncology market for HL is highly competitive, with a number of companies offering treatments and therapies. These include pharmaceutical companies such as AbbVie, Bristol-Myers Squibb, and Merck; biotechnology companies such as Gilead Sciences and Celgene; and medical device companies such as Medtronic and Stryker. Show Less Read more
